


Understanding menin inhibitors in AML



HOW DO MENIN INHIBITORS WORK?

- The protein **menin** binds its partner to switch on genes that let **leukemia cells keep growing**
- **Menin inhibitors** block this process, **slowing** the growth of the leukemia

Menin mechanism of action in AML



What menin inhibitors are available?

- **Revumenib** and **ziftomenib** - approved for treatment of people whose leukemia has returned after treatment (relapsed) or has not responded to previous therapies (refractory)
- **Bleximenib** and **enzomenib** - being studied in clinical trials

How are menin inhibitors used?

- **Effective** when used **alone** but **may be better** when used with other therapies - this is still being explored

What challenges are there?

Resistance (when treatment becomes less effective) **occurs by:**



Genetic changes (mutations) can make menin less responsive to treatment, so AML cells keep growing



Drug tolerant cells that survive and provide a source for the cancer to grow back from

Side effects:



Differentiation syndrome is a serious inflammatory condition - can occur with all menin inhibitors



A **change in heart rhythm** called QTc prolongation - occurs most with revumenib

FUTURE OF MENIN INHIBITOR USE

Researchers are also investigating combinations with **FLT3 inhibitors**, **CAR T-cell therapies**, and newer drugs such as **KAT6A/7 inhibitors**



Reference: Kühn M. Presentation at the EHA 2026 Congress, Stockholm, Sweden, June 12, 2026. Presentation ID p112-1. Armstrong S. Presentation at the EHA 2026 Congress, Stockholm, Sweden, June 12, 2026. Presentation ID p112-2. Garciaz S. Presentation at the EHA 2026 Congress, Stockholm, Sweden, June 12, 2026. Presentation ID p112-3.



ALAN
Acute Leukemia Advocates Network